ELEDON PHARMACEUTICALS INC(NASDAQ:ELDN) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to ELDN. ELDN was compared to 561 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ELDN as it has an excellent financial health rating, but there are worries on the profitability. ELDN is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

ELDN had negative earnings in the past year.

ELDN had a negative operating cash flow in the past year.

In the past 5 years ELDN always reported negative net income.

ELDN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -33.72%, ELDN is in the better half of the industry, outperforming 61.50% of the companies in the same industry.

The Return On Equity of ELDN (-50.63%) is better than 63.99% of its industry peers.

		Industry Rank	Sector Rank
ROA	-33.72%
ROE	-50.63%
ROIC	N/A

ROA(3y)-82.01%

ROA(5y)-55.57%

ROE(3y)-91.6%

ROE(5y)-61.56%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ELDN so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ELDN has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, ELDN has more shares outstanding

There is no outstanding debt for ELDN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

ELDN has an Altman-Z score of -1.60. This is a bad value and indicates that ELDN is not financially healthy and even has some risk of bankruptcy.

ELDN has a Altman-Z score (-1.60) which is in line with its industry peers.

There is no outstanding debt for ELDN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-1.6

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 12.42 indicates that ELDN has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 12.42, ELDN belongs to the top of the industry, outperforming 84.49% of the companies in the same industry.

A Quick Ratio of 12.42 indicates that ELDN has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 12.42, ELDN belongs to the top of the industry, outperforming 84.49% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	12.42
Quick Ratio	12.42

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 42.75% over the past year.

EPS 1Y (TTM)42.75%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%76.47%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ELDN will show a small growth in Earnings Per Share. The EPS will grow by 4.68% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-1.03%

EPS Next 2Y-2.9%

EPS Next 3Y-3.46%

EPS Next 5Y4.68%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ELDN. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ELDN. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as ELDN's earnings are expected to decrease with -3.46% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-2.9%

EPS Next 3Y-3.46%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ELDN!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ELEDON PHARMACEUTICALS INC

NASDAQ:ELDN (5/23/2025, 9:29:55 PM)

3.05

+0.03 (+0.99%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-14 2025-05-14/amc

Earnings (Next)08-18 2025-08-18

Inst Owners59.15%

Inst Owner Change0.57%

Ins Owners0.03%

Ins Owner Change0%

Market Cap182.63M

Analysts85

Price Target10.61 (247.87%)

Short Float %3.09%

Short Ratio7.89

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)153.48%

Min EPS beat(2)0.4%

Max EPS beat(2)306.56%

EPS beat(4)3

Avg EPS beat(4)18.31%

Min EPS beat(4)-242.52%

Max EPS beat(4)306.56%

EPS beat(8)6

Avg EPS beat(8)14.75%

EPS beat(12)9

Avg EPS beat(12)10.49%

EPS beat(16)11

Avg EPS beat(16)5.47%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-16.8%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-19.74%

EPS NY rev (1m)12.42%

EPS NY rev (3m)4.81%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.55
P/tB	2.13
EV/EBITDA	N/A

EPS(TTM)-0.79

EYN/A

EPS(NY)-1.11

Fwd EYN/A

FCF(TTM)-0.79

FCFYN/A

OCF(TTM)-0.79

OCFYN/A

SpS0

BVpS1.97

TBVpS1.43

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-33.72%
ROE	-50.63%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-82.01%

ROA(5y)-55.57%

ROE(3y)-91.6%

ROE(5y)-61.56%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	12.42
Quick Ratio	12.42
Altman-Z	-1.6

F-Score5

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)42.75%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%76.47%

EPS Next Y-1.03%

EPS Next 2Y-2.9%

EPS Next 3Y-3.46%

EPS Next 5Y4.68%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-89.42%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-19.59%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-19.59%

OCF growth 3YN/A

OCF growth 5YN/A

ELEDON PHARMACEUTICALS INC (ELDN) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens